Clinical stage immunotherapeutic biotechnology company Altimmune Inc ALT today had a large opening gap of 12.28%.
Photo taken from the Opening Gap Signals tool inside Benzinga Pro.
Why Is ALT Moving?
Altimmune shares are trading higher after the company agreed to acquire Spitfire Pharma, which will add a NASH drug candidate to the company's portfolio.
Photo taken from the ‘Why Is It Moving?’ Details tool inside Benzinga Pro.
For live updates on ALT, log in or try Benzinga Pro today.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.